Literature DB >> 19562274

Long-acting risperidone: a review of its role in the treatment of bipolar disorder.

David E Kemp1, Fatih Canan, Benjamin I Goldstein, Roger S McIntyre.   

Abstract

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562274      PMCID: PMC2878768          DOI: 10.1007/s12325-009-0039-0

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  40 in total

1.  Nonadherence with mood stabilizers: prevalence and predictors.

Authors:  Jan Scott; Marie Pope
Journal:  J Clin Psychiatry       Date:  2002-05       Impact factor: 4.384

2.  Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

Authors:  John M Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J Keith; Michael Lesem; Keith Karcher
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

3.  Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.

Authors:  Mariëlle Eerdekens; Ilse Van Hove; Bart Remmerie; Erik Mannaert
Journal:  Schizophr Res       Date:  2004-09-01       Impact factor: 4.939

4.  Excess mortality in bipolar and unipolar disorder in Sweden.

Authors:  U Osby; L Brandt; N Correia; A Ekbom; P Sparén
Journal:  Arch Gen Psychiatry       Date:  2001-09

Review 5.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

6.  Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.

Authors:  Mauricio Tohen; Terence A Ketter; Carlos A Zarate; Trisha Suppes; Mark Frye; Lori Altshuler; John Zajecka; Leslie M Schuh; Richard C Risser; Eileen Brown; Robert W Baker
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

Review 7.  Long-acting risperidone: a review of its use in schizophrenia.

Authors:  Tracy Swainston Harrison; Karen L Goa
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Mortality of patients with mood disorders: follow-up over 34-38 years.

Authors:  F Angst; H H Stassen; P J Clayton; J Angst
Journal:  J Affect Disord       Date:  2002-04       Impact factor: 4.839

Review 9.  Rapid-cycling bipolar disorder: effects of long-term treatments.

Authors:  L Tondo; J Hennen; R J Baldessarini
Journal:  Acta Psychiatr Scand       Date:  2003-07       Impact factor: 6.392

10.  Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.

Authors:  Robert M A Hirschfeld; Paul E Keck; Michelle Kramer; Keith Karcher; Carla Canuso; Marielle Eerdekens; Fred Grossman
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  8 in total

1.  Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder.

Authors:  Miguel A Boarati; Yuan-Pang Wang; Ana Paula Ferreira-Maia; Ana Rosa S Cavalcanti; Lee Fu-I
Journal:  Prim Care Companion CNS Disord       Date:  2013-05-02

Review 2.  Risperidone long-acting injection: in bipolar I disorder.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

3.  Saquinavir Loaded Acetalated Dextran Microconfetti - a Long Acting Protease Inhibitor Injectable.

Authors:  Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Craig D Sykes; Angela Kashuba; Kristy M Ainslie
Journal:  Pharm Res       Date:  2016-05-06       Impact factor: 4.200

4.  Long-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child.

Authors:  Sevcan Karakoç Demirkaya; Süleyman Salih Zoroğlu
Journal:  Noro Psikiyatr Ars       Date:  2016-04-15       Impact factor: 1.339

5.  Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection.

Authors:  Wissam El-Hage; Simon A Surguladze
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 6.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

7.  A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder.

Authors:  Yuan Hwa Chou; Po-Chung Chu; Szu-Wei Wu; Jen-Chin Lee; Yi-Hsuan Lee; I-Wen Sun; Chen-Lin Chang; Chien-Liang Huang; I-Chao Liu; Chia-Fen Tsai; Yung-Chieh Yen
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

8.  Smartphone Applications for Educating and Helping Non-motivating Patients Adhere to Medication That Treats Mental Health Conditions: Aims and Functioning.

Authors:  Angelos P Kassianos; Giorgos Georgiou; Electra P Papaconstantinou; Angeliki Detzortzi; Rob Horne
Journal:  Front Psychol       Date:  2017-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.